

## EAST AFRICAN SNAKEBITE SYMPOSIUM 12 June 2025



### Snake Anti-Venom: Poorly understood Essential Medicine

Dr. M.V. Khadilkar

Technical Director Premium Serums & Vaccines Pvt.Ltd., Narayangaon , Dist.-Pune (Maharashtra) INDIA E-mail: mvkhadilkar@premiumserums.com Website: www.premiumserums.com

# What is Snake Anti-Venom(SAV)

- It is a form of artificial passive immunization used to protect life of a patient at short notice like in life threatening medical emergency.
- Anti-Venom is a preparation of intact or fragmented immunoglobulin G [F(ab)<sub>2</sub> or F(ab)] used for treatment of severe envenoming from the bites of venomous animals.
- These readymade venom specific antibodies are raised in animal models(Equines/Sheep).
- It is a TRUE LIFESAVER

Antivenom is the only specific, time tested and proven therapy available for treatment of snake envenomation.

# SAV manufacturing process

- I) Horse Procurement
- 2) Immunization
  - (A)Primary immunization phase

Increasing sub-lethal doses of venoms

(B)Secondary immunization phase-Regular periodic boosters

- 3) Regular periodic Blood collection and Plasma separation
- 4) Plasma Fractionation

Enzymatic Digestion to yield F(ab')2 fragments

Separation of F(ab)2 fraction and concentration

- 6) Formulation, Vial filling & Lyophilisation
- 7) Quality checks and distribution

Usually it takes around 6-7 months to get product from animals after induction into program

## **How SAV acts**

- Prompt administration of adequate dose of ASV is of paramount importance for neutralization of unbound circulating snake venom components for early response to treatment.
- SAV is most effective when given intravenously.
- Any delay in administration may result in increased dose requirement and decreased effectiveness.
- SAV is effective to prevent or reverse most of the harmful effects of snakebite envenoming.
- When administered early, SAV is not just life-saving, but can also spare patients some of the suffering caused by necrotic and other toxins in snake venom, leading to faster recovery, less time in hospital and a more rapid transition back to a productive life.

#### SAV is the only specific antidote for snake envenomation

PANAF-Premium™ (Snake Venom Antiserum-Pan-Africa) Recommended for treatment of snakebites by African Adders Carpet vipers Spitting cobras Neurotoxic cobras Mambas

# WHO Risk-Benefit Assessment & Listing of Snake Antivenoms

- Process initiated in 2015
- It consisted of dossier desk review, independent laboratory evaluation of product, GMP verification audit of manufacturing facility.
- Manufacturing site approved by WHO in November 2019
- Bases on positive Risk-Benefit assessment by WHO, PANAF-Premium<sup>™</sup> has been approved and recommended for treatment of 24 medically important snake species in Sub Saharan Africa in March 2023.

# **PANAF-Premium**<sup>™</sup>

### (Pan-African Polyvalent Antivenom)



- <u>Specially developed in Lyophilized</u> form to avoid cold chain requirements.
- <u>Has shelf life of 4 years</u>
- <u>Snake venoms are sourced from Africa</u> for immunization
- <u>Distributed widely in Sub- Saharan</u> <u>African countries</u>
- Post Marketing Surveillance studies
  undertaken in many countries

### **Dose recommendations**

(1) Snake bite with Non-Neurotoxic Envenoming Syndrome-Bites by Carpet vipers (Echis spp.)-Administer initial dose of 1-3 vials Bites by African adders (Bitis spp.)-Administer initial dose of 3-6 vials Bites by African spitting cobras (Naja spp.) - Administer initial dose of 20-40vials

(2) Snake bite with Neurotoxic Envenoming Syndrome-Bites by Mambas (Dendroaspis spp.)- Administer initial dose of 10-25 vials

<u>Bites by Neurotoxic cobras (Naja spp.)-</u> Administer initial dose of **20-40 vials** 

# Venoms sourced from multiple origins

Snake Venom	Venom origins		
Bitis arietans	Namibia, Kenya,South Africa,Togo,Tanzania		
Bitis gabonica	Tanzania, DRC,South Africa,Zimbabwe		
Bitis nasicornis	Ghana, Uganda, Togo, DRC, Tanzania		
Bitis rhinoceros	Ghana, Togo		
Echis leucogaster	Niger, Ghana, Mali		
Echis ocellatus	Nigeria, Togo, Ghana, Cameroon, Benin		
Naja haje	Egypt, Morocco, Burkina Faso, Tanzania		
Naja melanoleuca	Togo, DRC, Uganda, Zimbabwe, South Africa, Tanzania, Cameroon		
Naja nigricollis	Togo, Tanzania, Cameroon, Ghana, Niger		
Dendroaspis polylepis	South Africa, Tanzania, Kenya		
Dendroaspis jamesoni	Uganda, DRC		
Dendroaspis viridis	Benin, Togo, Ghana		
Dendroaspis angusticeps	Zimbabwe, Tanzania, South Africa		

# Extensive Pre-clinical assessment by independent research groups

- I.Preclinical evaluation of three polyspecific antivenoms against the venom of Echis ocellatus: Neutralization of toxic activities and antivenomics: Toxicon I 19(2016) pp 280-288
- 2. The medical threat of mamba envenoming in Sub-saharan Africa revealed by genus-wide analysis of venom...: Journal of Proteomics; August (2017)
- 3.Preclinical antivenom-efficacy testing reveals potential disturbing deficiencies of snakebite treatment capability in East Africa: PLOS-Neglected Tropical Disease-October 18,(2017)
- 4. Assessment of quality, safety, and pre-clinical toxicity of an equine polyvalent antisnake venom (Pan Africa): Determination of immunological cross-reactivity of antivenom against venom samples of Elapidae and Viperidae snakes of Africa: Toxicon 153 (2018) 120–127
- 5. Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa: Int. J. Mol. Sci.(2024), 25, 4213.

#### **PANAF-Premium**<sup>™</sup>

#### (Pan-African Polyvalent Antivenom)

Dendroaspis polylepis (Black mamba)
Dondrogobie ignoconi (lanceconie membre)
Dendroaspis jamesoni (Jameson's mamba)
Dendroaspis angusticeps (Eastern green mamba)
Dendroaspis viridis (Western green mamba )
Bitis arietans (Puff adder)
Bitis nasicornis (Nose-horned viper)
Bitis gabonica (Gaboon viper )
Bitis rhinoceros (Rhinoceros viper)
Echis ocellatus (West African carpet viper)
Echis leucogaster (White-bellied carpet viper)
Echis pyramidum (East African carpet viper )
Echis romani (Roman's carpet viper )

Additionally it has shown cross-neutralization of venoms of N.ashei, N.nubiae, N.nivea and N.woodi

(Khochare, S.; Jaglan, A.; Rashmi, U.; Dam, P.; Sunagar, K.: Harnessing the Cross-Neutralisation Potential of Existing Antivenoms for Mitigating the Outcomes of Snakebite in Sub-Saharan Africa. Int. J. Mol. Sci. 2024, 25, 4213. https://doi.org/10.3390/ijms25084213

# **Status in Kenya**

- PANAF-Premium<sup>™</sup> is registered with PPB
- It has been supplied to KEMSA and widely distributed in health care facilities in Kenya.
- Training of Health Care Workers have been carried out at key locations
- Currently multicentric Post Marketing Surveillance study is going on in Kenya
- Distributor in Kenya

Nairobi Enterprises,

Saachi Plaza B-Wing I, Argwings Kodhek Road, Kilimani, P.O.Box 42367-00100, Nairobi, KENYA.

# Status in East African countries


Name of country	Distributor 's name	Registration status	Remark
Burundi	Alchem Industries SURL 13, Rue Da La Victorie, B.P. 2491 Bujumbura, BURUNDI	Under Registration	-
Rwanda	<b>Depot Pharmaceutique Le Medical</b> P.O.Box 5353 Kigali, RWANDA.	Under Registration	-
South Sudan			Supply thro' WHO
Tanzania	<b>Kastipharm Ltd</b> Haidery Plaza, Plot 519/14 Block 14 Kistu/Upanga Street, Dar Es Sallam, TANZANIA.	Registered	-
Uganda	<b>Norvik Enterprise</b> 78/3, Kampala Road, P.O.Box. 21034, Kampala, UGANDA.	Under Registration	-

#### **Product has been supplied in these countries**

# **PANAF-Premium<sup>™</sup> is widely distributed**

- South Africa, Botswana, Lesotho, Uganda, Gambia, Malawi, Zimbabwe, South Sudan, Kenya, Tanzania, Rwanda, Burundi, Congo, Namibia, Angola, Zambia, Mozambique, Cameroon, Togo, Ghana, Nigeria, Eritrea, Ethiopia, Gabon, Mauritania, Mali, Spain, Netherlands and USA
- Also to various countries through UNICEF, MSF & WHO

# **Case Report**



#### 10:22 👂 👂



NSAG Andries, Jess Briner, +27 66 242 6233,.

🖙 🙃 ୪ଝି ୮୮ 29% 💼

·I I·

~»

٢

2,4m black mamba, Barberton, Mpumalanga

Patient presented with early excessive diaphoresis, tingling sensation in the mouth. Arrived at Nelspruit Mediclinic approximately 42 Min after the bite high up on his right thigh.

Rapid onset of neurotoxic symptoms continued indicating clear signs of progressive weakness syndrome. In consultation Dr K Venter and Jason Seale, it was decided to administer 15 vials of Panaf Premium.

After a 30 Min infusion of the Panaf Premium, the patient showed a marked turn around , with no noteworthy allergic reactions and has made a full recovery.

Thank you to Jason for your invaluable advice and to Dr K Venter for your amazing work done on this case and for logging the details on the NSAG database

#### 3 unread messages

 $\bigcirc$ 

O

രി

<

# Thanks for your attention